Salarius Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results and Highlight Recent Company Progress
Salarius Pharmaceuticals (Nasdaq: SLRX) will host a conference call and audio webcast on March 10, 2022, at 5:00 p.m. ET to discuss its financial results for the year ended December 31, 2021. The call will provide insights into its clinical developments, including seclidemstat, a cancer therapy in Phase 1/2 trials for Ewing sarcoma. The company has secured Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA for this indication. Interested participants can join via provided U.S. and international phone numbers.
- Seclidemstat is under Phase 1/2 clinical trial for Ewing sarcoma and related cancers.
- The drug has received Fast Track, Orphan Drug, and Rare Pediatric Disease Designations from the FDA.
- Financial support from the National Pediatric Cancer Foundation and CPRIT to advance clinical programs.
- None.
Conference Call and Live Audio Webcast Scheduled for Thursday, March 10, 2022, 5:00 p.m. ET
HOUSTON, March 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today announced that the Company will host a conference call and live audio webcast on Thursday, March 10, 2022, at 5:00 p.m. ET, to discuss its corporate and financial results for the three and 12 months ended December 31, 2021.
Conference Call Information:
Interested participants and investors may access the conference call by dialing either:
- (833) 423-0481 (U.S.)
- (918) 922-2375 (International)
- Conference ID: 7375449
An audio webcast will be accessible via the Investors Events and Presentations section of the Company’s website http://investors.salariuspharma.com/. An archive of the webcast will remain available for 90 days beginning at approximately 6:00 p.m. ET, on March 10, 2022.
About Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers, initiated by MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
Lisa Sher
lsher@tiberend.com
Media Relations
Tiberend Strategic Advisors, Inc.
Johanna Bennett
jbennett@tiberend.com
FAQ
When is the Salarius Pharmaceuticals conference call scheduled?
What is the purpose of the Salarius Pharmaceuticals conference call?
What clinical trials is Salarius Pharmaceuticals currently conducting?
What designations has seclidemstat received from the FDA?
